Osteopontin predicts the behaviour of atypical meningioma

Histopathology

Volumn 60, Issue 2, 2012, Pages 320-325

  Lin, Chih Kung ^a   Tsai, Wen Chiuan ^a   Lin, Yu Chun ^a   Hueng, Dueng Yuan ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Cortactin; Immunohistochemical score; Meningioma; Osteopontin

Indexed keywords

CORTACTIN; OSTEOPONTIN;

ADULT; AGED; ARTICLE; ATYPICAL MENINGIOMA; BEHAVIOR; CANCER GRADING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT MENINGIOMA; MENINGIOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SCORING SYSTEM; TUMOR CLASSIFICATION; TUMOR RECURRENCE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; CORTACTIN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 84255199139     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04085.x     Document Type: Article

References (27)

1. Kayaselçuk F, Zorludemir S, Bal N, Erdogan B, Erdogan S, Erman T. The expression of survivin and Ki-67 in meningiomas: correlation with grade and clinical outcome. J. Neurooncol. 2004; 67; 209-214.
2. Scheithauer BW. Tumors of the meninges: proposed modifications of the World Health Organization classification. Acta Neuropathol. 1990; 80; 343-354.
3. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumors. Brain Pathol. 1993; 3; 255-268.
4. Kepes JJ. Presidential address: the histopathology of meningiomas a reflection of origins and expected behavior? J. Neuropathol. Exp. Neurol. 1986; 45; 95-106.
5. Thomas HG, Clarisse LD, Berry K. Malignant meningioma: clinical and pathological features. J. Neurosurg. 1981; 55; 929-934.
6. Ohta M, Iwaki T, Kitamoto T, Takeshita I, Tateishi J, Fukui M. MIB1 staining index and scoring of histologic features in meningioma. Cancer 1994; 74; 3176-3189.
7. Chakraborty G, Jain S, Behera R et al. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr. Mol. Med. 2006; 6; 819-830.
8. Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J. Cell. Biochem. Suppl. 1998; 30-31; 92-102.
9. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim. Biophys. Acta 2001; 1552; 61-85.
10. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr. Mol. Med. 2001; 1; 621-632.
11. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: clinical and experimental studies. J. Mammary Gland Biol. Neoplasia 2001; 6; 419-429.
12. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J. Cell. Biochem. 2000; 78; 465-475.
13. Toy H, Yavas O, Eren O, Genc M, Yavas C. Correlation between osteopontin protein expression and histological grade of astrocytomas. Pathol. Oncol. Res. 2009; 15; 203-207.
14. Tunio GM, Hirota S, Nomura S, Kitamura Y. Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer. Arch. Pathol. Lab. Med. 1998; 122; 1087-1090.
15. Daly RJ. Cortactin signaling and dynamic actin networks. Biochem. J. 2004; 382; 13-25.
16. Van Rossum AG, Moolenaar WH, Schuuring E. Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. Exp. Cell Res. 2006; 312; 1658-1670.
17. Weaver AM, Karginov AV, Kinley AW et al. Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation. Curr. Biol. 2001; 11; 370-374.
18. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res. Treat. 2003; 78; 323-335.
19. Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes - a review. Gene 1995; 159; 83-96.
20. Tsai WC, Jin JS, Chang WK et al. Association of cortactin and fascin-1 expression in gastric adenocarcinoma: correlation with clinocopathological parameters. J. Histochem. Cytochem. 2007; 55; 955-962.
21. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB1 monoclonal antibody on archival material. Acta Neuropathol. 1994; 87; 47-54.
22. Ho DM, Hsu CY, Ting LT, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 2002; 94; 1538-1547.
23. Tseng KY, Chung MH, Sytwu HK et al. Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J. Neurooncol. 2010; 100; 217-223.
24. Laurendeau I, Ferrer M, Garrido D et al. Gene expression profiling of the hedgehog signaling pathway in human meningiomas. Mol. Med. 2010; 16; 262-270.
25. Van Rossum AG, Gibcus J, van der Wal J, Schuuring E. Cortactin overexpression results in sustained epidermal growth factor receptor signaling by preventing ligand-induced receptor degradation in human carcinoma cells. Breast Cancer Res. 2005; 7; 235-237.
26. Weed SA, Parsons JT. Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 2001; 20; 6418-6434.
27. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8; 138-140. [in German].